Latest Headlines

  1. RoosterBio And Secretome Therapeutics Announce Successful Completion Of Large Scale Bioreactor Production For Clinical Stage Cell Therapy Candidate STM-01 10/6/2025

    RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC) today announced completion of commercial scale production of Secretome’s lead nCPC, STM-01.

  2. AAV Producer Cell Lines, A New Standard For Viral Vector Manufacturing 10/6/2025

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of its AAV Edge Stable Producer System. With this launch, Asimov aims to address the shortcomings of traditional transient transfection-based production and bring AAV manufacturing standards closer to those established for antibody-based biologics.

  3. Avance Clinical Accelerates Time To Pivotal Milestones For More Than 700 Emerging Biotechs 9/30/2025

    Avance Clinical, a partner for biotechs providing global contract research organization services, has now guided 710 emerging biotechs through critical clinical trial inflection points.

  4. Avance Clinical Attends Reception Welcoming Australia's US Ambassador To North Carolina Governor's Executive Mansion In Raleigh, N.C. 9/30/2025

    Avance Clinical was honored to attend a special reception at the Executive Mansion in Raleigh, North Carolina, hosted by Governor Josh Stein to welcome His Excellency, The Honorable Kevin Rudd AC, Australia’s Ambassador to the United States.

  5. Avance Clinical Strengthens Korea Focus: Seoul Meeting Highlights Growth, Partnerships, And Regional Collaboration 9/30/2025

    Avance Clinical, a global CRO headquartered in South Australia, met with Mr Jeff Robinson, South Australian Ambassador to Korea, to advance collaboration opportunities between South Australia and Korea in biotech clinical research.

  6. ProBioGen To Lead GMP Manufacturing Operations At Berlin Center For Gene And Cell Therapies (BC GCT) 9/16/2025

    ProBioGen will oversee the design, lead the construction, and subsequently operate the 4,600-square-meter GMP manufacturing unit — an integral part of the center, envisioned as a powerhouse for translational medicine and innovation in Berlin and beyond.

  7. FUJIFILM Biosciences Introduces BalanCD HEK293 Perfusion A Medium To Enable Gene Therapy Production 9/15/2025

    FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the Life Science market, today announced the commercial launch of BalanCD HEK293 Perfusion A.

  8. Results Of Nanoform Collaborative Study To Be Presented At U.S. Drug Delivery & Formulation (DDF) Summit 9/11/2025

    Nanoform, a leading nanoparticle medicine performance-enhancing company, announced that key findings from two studies conducted in collaboration between Nanoform and Takeda will be presented at the 15th American Drug Delivery & Formulation Summit (DDF) in Boston, Mass., on September 16, 2025, at 09:10 – 09:40 in Room 1.

  9. Eppendorf Announces Stem Cell Community Day 2025: Uniting Innovators In Stem Cell Bioprocessing 9/4/2025

    Eppendorf is excited to announce the upcoming 6th Stem Cell Community Day. Held for the first time 2017, it quickly evolved to a premier event designed to bring together leading minds from industry and academia to explore the latest advancements, challenges, and opportunities in the bioprocessing of cells for advanced therapies. This year’s event will take place on November 4–5, 2025 in Copenhagen, Denmark and offers a dynamic platform for scientific exchange, collaboration, and networking.

  10. Andelyn Biosciences And Tern Therapeutics Partner For Late-Stage Process Performance Qualification (PPQ) Manufacturing Of AAV Gene Therapy For The Treatment Of CLN2 Batten Disease 9/3/2025

    Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Tern Therapeutics (Tern) to perform late-stage Process Performance Qualification (PPQ) manufacturing of Tern's TTX-381 program.